Live Analyst Rating Changes 5087 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Geulah Livshits
CHAR
Geulah Livshits
Wall Street Analyst
★★★☆☆
#1582
on 13Foresight · ranked by our own returns
46%
Success Rate
+26.4%
Average Return
17 of 37 calls profitable · +18.3% vs benchmark
📈 Across the calls we could measure, roughly 46% of Geulah Livshits's ratings turned a profit when each position was held for 1 year — averaging +26.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

79 Buy 1 Hold 0 Sell
Geulah's Stock Coverage 40 ratings · 2026-07-05
Company Date Position Consensus Price Target 1-Yr Return
PVLA
Palvella Therapeutics
May 20, 2026 BUY Strong Buy
+13.2% avg upside
27 analysts
$240.00
63.52% Upside
+27.1%
IMRX
Immuneering
May 19, 2026 BUY Strong Buy
+243.2% avg upside
10 analysts
$20.00
285.34% Upside
+3.3%
IMTX
Immatics
May 19, 2026 BUY Strong Buy
+83.6% avg upside
15 analysts
$25.00
151.16% Upside
·
TNYA
Tenaya Therapeutics
May 15, 2026 BUY Strong Buy
+1174.3% avg upside
11 analysts
$8.00
916.56% Upside
+0.0%
SNTI
Senti Biosciences
May 15, 2026 BUY Strong Buy
+717.7% avg upside
7 analysts
$12.00
1021.44% Upside
-5.9%
SLDB
Solid Biosciences
May 13, 2026 BUY Strong Buy
+46.2% avg upside
23 analysts
$15.00
38.47% Upside
+36.6%
MGX
Metagenomi, Inc.
May 13, 2026 BUY Strong Buy
+693.6% avg upside
7 analysts
$7.00
455.52% Upside
-9.4%
LXEO
Lexeo Therapeutics, Inc.
May 11, 2026 BUY Strong Buy
+312.9% avg upside
11 analysts
$17.00
262.47% Upside
-16.8%
RCKT
Rocket Pharmaceuticals
May 10, 2026 BUY Buy
+329.4% avg upside
29 analysts
$11.00
186.37% Upside
-17.5%
PRME
Prime Medicine, Inc.
May 08, 2026 BUY Strong Buy
+152.4% avg upside
16 analysts
$9.00
132.52% Upside
+16.0%
FDMT
4D Molecular Therapeutics
May 08, 2026 BUY Strong Buy
+171.4% avg upside
15 analysts
$26.00
100.09% Upside
-9.8%
IOVA
Iovance Biotherapeutics
May 07, 2026 BUY Buy
+195.5% avg upside
24 analysts
$14.00
224.82% Upside
-2.8%
TSHA
Taysha Gene Therapies
May 06, 2026 BUY Strong Buy
+111.0% avg upside
21 analysts
$12.00
83.76% Upside
-6.5%
CLYM
Climb Bio
May 05, 2026 BUY Strong Buy
+40.1% avg upside
18 analysts
$22.00
70.56% Upside
-5.7%
EDIT
Editas Medicine
May 05, 2026 BUY Buy
+274.4% avg upside
33 analysts
$4.00
9.64% Upside
-13.0%
KRYS
Krystal Biotech
May 04, 2026 BUY Strong Buy
-33.4% avg upside
19 analysts
$323.00
13.96% Downside
+30.7%
CRSP
Crispr Therapeutics AG
May 04, 2026 BUY Buy
+25.2% avg upside
41 analysts
$76.00
26.41% Upside
+12.1%
NTLA
Intellia Therapeutics
Apr 27, 2026 BUY Buy
+124.8% avg upside
37 analysts
$30.00
70.77% Upside
+34.7%
PASG
Passage Bio
Nov 12, 2025 BUY Buy
+275.1% avg upside
14 analysts
$21.00
348.73% Upside
-45.4%
MRNA
Moderna
Oct 07, 2025 HOLD Hold
-13.7% avg upside
38 analysts
+191.7%
FR:ALSEN
Sensorion SAS
Sep 17, 2025 BUY Strong Buy
+550.9% avg upside
5 analysts
$1.00
284.58% Upside
·
IPSC
Century Therapeutics
Mar 24, 2025 BUY Strong Buy
+119.2% avg upside
11 analysts
$7.00
188.16% Upside
+283.6%
ABUS
Arbutus Biopharma
Jan 29, 2024 BUY Strong Buy
+81.4% avg upside
15 analysts
+33.1%
MGTX
Meiragtx Holdings
Dec 21, 2023 BUY Strong Buy
+87.4% avg upside
13 analysts
$36.00
158.70% Upside
-5.5%
QURE
uniQure
Aug 25, 2023 BUY Strong Buy
+41.3% avg upside
29 analysts
-27.8%
CABA
Cabaletta Bio
Mar 21, 2023 BUY Strong Buy
+336.2% avg upside
16 analysts
$12.00
276.16% Upside
+126.9%
PDSB
PDS Biotechnology
Feb 17, 2023 HOLD Strong Buy
+1683.4% avg upside
11 analysts
-38.7%
GYRE
Gyre Therapeutics
Jan 06, 2023 HOLD Strong Buy
+165.6% avg upside
15 analysts
+298.6%
PAGS
Pagseguro Digital
Dec 14, 2022 BUY Buy
+54.9% avg upside
18 analysts
$11.00
20.54% Upside
+33.7%
SQZB
SQZ Biotechnologies
Dec 01, 2022 BUY Buy
+102677.7% avg upside
7 analysts
$40.00
166566.59% Upside
-98.7%
FR:SIGHT
GenSight Biologics SA
Jul 28, 2022 BUY Strong Buy
+17972.3% avg upside
3 analysts
$15.00
17972.28% Upside
·
RGNX
RegenXBio
Mar 29, 2022 BUY Strong Buy
+184.4% avg upside
22 analysts
$76.00
472.20% Upside
-43.2%
VYGR
Voyager Therapeutics
Mar 09, 2022 HOLD Strong Buy
+279.0% avg upside
23 analysts
$6.00
58.66% Upside
+25.6%
QTTB
Q32 Bio
Feb 22, 2022 BUY Buy
+304.7% avg upside
24 analysts
$15.00
14.55% Upside
-48.5%
IMVT
Immunovant
Jan 05, 2022 BUY Strong Buy
-0.4% avg upside
24 analysts
$20.00
48.38% Downside
+146.4%
IMNM
Immunome
Aug 20, 2021 BUY Strong Buy
+43.3% avg upside
16 analysts
$21.00
11.00% Downside
-58.0%
NTBLQ
Notable Labs
Jul 30, 2021 HOLD Buy
+809999900.0% avg upside
12 analysts
·
REPL
Replimune Group
Oct 14, 2020 BUY Buy
+77.5% avg upside
13 analysts
$48.00
314.60% Upside
-14.2%
NAUT
Nautilus Biotechnolgy
Jun 04, 2020 BUY Strong Buy
+564.8% avg upside
5 analysts
$28.00
1518.50% Upside
-3.1%
FBRX
Forte Biosciences
Feb 20, 2020 HOLD Strong Buy
+94.5% avg upside
14 analysts
$1.00
95.30% Downside
+139.8%
🔒 35 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Geulah Livshits — Frequently Asked Questions
How accurate are Geulah Livshits's stock ratings?
Based on the calls 13Foresight could measure, about 46% of Geulah's ratings were profitable over a one-year hold, with an average return of +26.4% per rating, or +18.3% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Geulah ranked on 13Foresight?
Geulah Livshits is currently ranked #1582 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Geulah cover?
Geulah most recently has ratings on PVLA, IMRX, IMTX, TNYA, SNTI, SLDB, MGX, LXEO, RCKT, PRME, FDMT, IOVA and 28 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.